Germany-based molecular diagnostics company Curetis expanded its series A round on Wednesday to €34m ($48.3m). The additional investment of €9.6m was provided by Roche Venture Fund, the corporate venturing unit of Swiss pharmaceutical company Roche, and venture capital (VC) firms Forbion Capital Partners and CD-Venture.

Other investors in Curetis’ series A round prior to this week are CD-Venture, German government-owned development bank KfW Bankengruppe, private equity funds Aeris Capital and Life Sciences Partners, and VC firm BioMed Partners. Altogether, Curetis…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?